Privia Health Group, Inc.
NASDAQ:PRVAMedical - Healthcare Information Services
+$0.15 today
- Market cap
- $3.14B
- Beta
- 0.87
- P/E (TTM)
- 134.4
- EPS (TTM)
- $0.18
Volume 2.38M
Average 0.95M
PRVA Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Privia Health Group, Inc.NASDAQ: PRVA
Revenue · Q2 FY2026 · quarter ended Jun 2026
Revenue grows, but more slowly than its trailing trend
Q2 FY2026 revenue of $632.63M rose 21.4% year over year, behind the +24.1% change in trailing-twelve-month revenue. Sequentially, it rose 4.8% from the prior quarter. Over 3 fiscal years it compounded at +16.1% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 10 analysts of $2.53B (+19.1%) for the fiscal year ending Dec 2026, a slowdown from the +22.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $632.63M+4.8% QoQ
- Last fiscal yearDec 2025
- $2.12B+22.3% YoY
- LTMJun 2026
- $2.36B+24.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +21.4% | +5.2% | -16.2 pp |
| 1 year | +22.3% | +19.1% | -3.1 pp |
| 3-year CAGR | +16.1% | +13.2% | -2.9 pp |
| 5-year CAGR | +11.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 2.12B USD
- Year-over-year change
- +22.3%
- 4-year CAGR
- +21.7%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.12B | +22.3% |
| FY2024 | 2024-12-31 | 1.74B | +4.7% |
| FY2023 | 2023-12-31 | 1.66B | +22.2% |
| FY2022 | 2022-12-31 | 1.36B | +40.4% |
| FY2021 | 2021-12-31 | 966.22M | — |
Revenue vs competitors
How PRVA compares with its peers on the latest reported figures
- PRVA's LTM Jun 2026 revenue of $2.36B is the 4th highest of the 10 companies compared; the peer median is $495.59M.
- Its year-over-year change of +24.1% is the 3rd highest of 10, against a peer median of -1.5%.
- Over three fiscal years its annual growth of +16.1% compares with a peer median of +11.5%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $5.82B | -2.8% | +35.4% | |
| LTM Mar 2026 | $3.53B | +56.7% | +40.6% | |
| LTM Mar 2026 | $2.51B | -1.5% | +1.7% | |
| LTM Jun 2026 | $2.36B | +24.1% | +16.1% | |
| LTM Mar 2026 | $1.89B | -21.3% | +11.5% | |
| LTM Apr 2026 | $495.59M | +14.1% | +19.6% | |
| LTM Mar 2026 | $302.48M | -2.8% | +4.0% | |
| LTM Mar 2026 | $283.3M | +49.4% | +42.9% | |
| LTM Mar 2026 | $237.38M | -9.3% | -3.5% | |
| LTM Mar 2026 | $124.14M | +10.3% | -4.6% | |
| Peer median (excluding PRVA) | $495.59M | -1.5% | +11.5% | |
Competitors are the stored peer set for PRVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 966.22M | 1.36B | 1.66B | 1.74B | 2.12B |
| Cost of Revenue | 902.56M | 1.22B | 1.5B | 1.56B | 1.91B |
| Gross Profit | 63.66M | 134.78M | 161.5M | 176.85M | 209.43M |
| Gross Margin | 6.6% | 9.9% | 9.7% | 10.2% | 9.9% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 278.63M | 149.33M | 134.32M | 152.6M | 165.29M |
| Operating Expenses | 281.1M | 153.9M | 140.85M | 159.87M | 175.2M |
| Depreciation & Amortization | 2.46M | 4.57M | 6.53M | 7.27M | 9.91M |
| EBITDA | (214.97M) | (14.01M) | 35.55M | 35.14M | 53.85M |
| EBITDA Margin | -22.2% | -1.0% | 2.1% | 2.0% | 2.5% |
| Operating Income | (217.44M) | (19.12M) | 20.65M | 16.98M | 34.24M |
| Operating Margin | -22.5% | -1.4% | 1.2% | 1.0% | 1.6% |
| Interest Income | 0 | 542K | 8.37M | 10.89M | 9.7M |
| Interest Expense | 1.07M | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (1.07M) | 542K | 8.37M | 10.89M | 9.7M |
| Income Before Tax | (218.51M) | (18.58M) | 29.02M | 27.87M | 43.94M |
| Pre-Tax Margin | -22.6% | -1.4% | 1.8% | 1.6% | 2.1% |
| Income Tax Expense | (27.86M) | (6.52M) | 7.99M | 10.83M | 14.21M |
| Net Income | (188.23M) | (8.59M) | 23.08M | 14.39M | 22.92M |
| Net Margin | -19.5% | -0.6% | 1.4% | 0.8% | 1.1% |
| EPS (Basic) | (1.77) | (0.08) | 0.20 | 0.12 | 0.19 |
| EPS (Diluted) | (1.77) | (0.08) | 0.19 | 0.11 | 0.18 |
| Weighted Avg Shares | 107.84M | 110.7M | 116.73M | 119.4M | 122.18M |
| Weighted Avg Shares (Diluted) | 107.84M | 110.7M | 124.69M | 125.61M | 128.89M |
Privia Health Group, Inc.
NASDAQ:PRVA
Intrinsic Alpha fair value
Locked
Current Price
$24.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.